Tourmaline Bio (TRML)

• Market cap: $384M
• 1 day: -1.64%
• 5 days: -12.00%
• 1 month: 21.33%
• 3 months: -27.52%
• 6 months: -42.97%
• Year to date: -27.52%
• 1 year: -36.45%
• 5 years: -7.94%
• 10 years: -7.94%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

82% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 22

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

10% more funds holding

Funds holding: 92 [Q3] → 101 (+9) [Q4]

7.08% more ownership

Funds ownership: 82.09% [Q3] → 89.17% (+7.08%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]

14% less capital invested

Capital invested by funds: $541M [Q3] → $464M (-$77.5M) [Q4]

65% less call options, than puts

Call options by funds: $89K | Put options by funds: $251K

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $43 187% upside
• Avg. target: $50 236% upside
• High target: $58 288% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Wedbush Laura Chico 19% 1-year accuracy 10 / 54 met price target	187% upside $43	Outperform Maintained	14 Mar 2025
HC Wainwright & Co. Yi Chen 38% 1-year accuracy 63 / 167 met price target	234% upside $50	Buy Maintained	14 Mar 2025
LifeSci Capital Jimmy Shan 38% 1-year accuracy 3 / 8 met price target	288% upside $58	Outperform Initiated	24 Feb 2025